{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:31:17Z","timestamp":1761492677477,"version":"build-2065373602"},"reference-count":11,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofdiabetes.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Diabetes"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.jcjd.2014.06.001","type":"journal-article","created":{"date-parts":[[2014,8,2]],"date-time":"2014-08-02T15:30:28Z","timestamp":1406993428000},"page":"219-220","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Canada Welcomes a Novel Class of Oral Glucose-Lowering Drugs for People with\u00a0Type 2 Diabetes"],"prefix":"10.1016","volume":"38","author":[{"given":"David C.W.","family":"Lau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjd.2014.06.001_bib1","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.jcjd.2013.01.016","article-title":"Targets for glycemic control","volume":"37","author":"Canadian Diabetes Association Clinical Practice Guidelines Expert Committee","year":"2013","journal-title":"Can J Diabetes"},{"issue":"Suppl 1","key":"10.1016\/j.jcjd.2014.06.001_bib2","first-page":"S61","article-title":"Pharmacologic management of type 2 diabetes","volume":"37","author":"Canadian Diabetes Association Clinical Practice Guidelines Expert Committee","year":"2013","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jcjd.2014.06.001_bib3","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1111\/dom.12116","article-title":"Cardiovascular safety of sulfonylureas: A meta-analysis of randomized clinical trials","volume":"15","author":"Monami","year":"2013","journal-title":"Diab Obes Metab"},{"key":"10.1016\/j.jcjd.2014.06.001_bib4","doi-asserted-by":"crossref","first-page":"e1369","DOI":"10.1136\/bmj.e1369","article-title":"Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis","volume":"344","author":"Karagiannis","year":"2012","journal-title":"BMJ"},{"key":"10.1016\/j.jcjd.2014.06.001_bib5","doi-asserted-by":"crossref","first-page":"516","DOI":"10.2337\/dc13-0600","article-title":"Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: Silent hypoglycemias and silent arrhythmias","volume":"37","author":"Stahn","year":"2014","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2014.06.001_bib6","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.2337\/dc09-2082","article-title":"Hypoglycemia, diabetes, and cardiovascular events","volume":"33","author":"Desouza","year":"2010","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2014.06.001_bib7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jcjd.2013.02.055","article-title":"Type 2 diabetes mellitus management in Canada: Is it improving?","volume":"37","author":"Leiter","year":"2013","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jcjd.2014.06.001_bib8","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd3180","article-title":"SGLT2 inhibition: A novel strategy for diabetes treatment","volume":"9","author":"Chao","year":"2010","journal-title":"Nature Rev Drug Discov"},{"key":"10.1016\/j.jcjd.2014.06.001_bib9","doi-asserted-by":"crossref","first-page":"262","DOI":"10.7326\/0003-4819-159-4-201308200-00007","article-title":"Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis","volume":"159","author":"Vasilakou","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jcjd.2014.06.001_bib10","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.2337\/dc12-2491","article-title":"Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: A 52-week randomized trial","volume":"36","author":"Schernthaner","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2014.06.001_bib11","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.2337\/dc13-2338","article-title":"Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: Results of an 8-week open-label proof-of-concept trial","volume":"37","author":"Perkins","year":"2014","journal-title":"Diabetes Care"}],"container-title":["Canadian Journal of Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267114002391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267114002391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T15:25:20Z","timestamp":1761492320000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1499267114002391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":11,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S1499267114002391"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjd.2014.06.001","relation":{},"ISSN":["1499-2671"],"issn-type":[{"type":"print","value":"1499-2671"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Canada Welcomes a Novel Class of Oral Glucose-Lowering Drugs for People with\u00a0Type 2 Diabetes","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjd.2014.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}